Sugi Predict

Sugi Predict / Compounds / SCHEMBL1921150

SCHEMBL1921150

SCHEMBL1921150

CC(C)(C)OC(=O)c1ccc(CC(C(=O)O)c2ccc(Br)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.44
▸ CTSS P25774 1/20 0.44
▸ CTSK P43235 1/20 0.44
▸ SLC7A5 Q01650 1/20 0.43
▸ MME P08473 3/20 0.43
▸ PTGS1 P23219 2/20 0.42
▸ PTGS2 P35354 2/20 0.42
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ ESR1 P03372 3/20 0.39
▸ ESR2 Q92731 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ PPARG P37231 3/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ PPARA Q07869 2/20 0.38
▸ PPARD Q03181 1/20 0.38
▸ CA12 O43570 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921149 1.00 KMT2A (0.44) KMT2ACTSSCTSKSLC7A5MME
SCHEMBL28100731 1.00 KMT2A (0.44) KMT2ACTSSCTSKSLC7A5MME
SCHEMBL13494499 0.88 SLC7A5 (0.44) SLC7A5PTGS1PTGS2CYP2C9CYP2C19
SCHEMBL17338896 0.88 ESRRG (0.37) KMT2ACTSSCTSKSLC7A5MME
SCHEMBL17338899 0.88 ESRRG (0.37) KMT2ACTSSCTSKSLC7A5MME
SCHEMBL1919196 0.88 ESR1 (0.56) KMT2ACTSSCTSKSLC7A5MME
SCHEMBL23306974 0.85 ESR1 (0.44) KMT2ACTSSCTSKSLC7A5MME
SCHEMBL13494459 0.85 SLC7A5 (0.48) CTSSCTSKSLC7A5MMEALDH1A1
SCHEMBL1919093 0.85 SLC7A5 (0.48) CTSSCTSKSLC7A5MMEALDH1A1
SCHEMBL1918994 0.85 ESR1 (0.48) KMT2APTGS1PTGS2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12208071-B2 Glucagon receptor antagonists LIGAND PHARMACEUTICALS INCORPORATED (US) 2025-01-28 — — US disclosed
US-11352321-B2 Glucagon antagonists METABASIS THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210121422-A1 GLUCAGON RECEPTOR ANTAGONISTS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2021-04-29 — — US disclosed
CN-107428682-B Amide derivatives, preparation method and medical application thereof 浙江海正药业股份有限公司 2021-02-02 — — CN disclosed
EP-3752249-A1 GLUCAGON RECEPTOR ANTAGONISTS Ligand Pharmaceuticals, Inc. (US) 2020-12-23 — — EP disclosed
CN-111954560-A Glucagon receptor antagonists 配体药物公司 2020-11-17 — — CN disclosed
US-20190330144-A1 GLUCAGON ANTAGONISTS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-10-31 — — US disclosed
WO-2019160940-A1 GLUCAGON RECEPTOR ANTAGONISTS LIGAND PHARMACEUTICALS INCORPORATED (US) 2019-08-22 — — WO disclosed
WO-2019160940-A1 GLUCAGON RECEPTOR ANTAGONISTS LIGAND PHARMACEUTICALS INCORPORATED (US) 2019-08-22 — — WO disclosed
US-20190099391-A1 Glucagon Antagonists LIGAND PHARMACEUTICALS, INC. (US) 2019-04-04 — — US disclosed
EP-2799428-B1 Glucagon antagonists METABASIS THERAPEUTICS INC (US) 2016-11-16 — — EP disclosed
WO-2015191900-A1 GLUCAGON ANTAGONISTS LIGAND PHARMACEUTICALS, INC. (US) 2015-12-17 — — WO disclosed
US-20150087680-A1 GLUCAGON ANTAGONISTS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-03-26 — — US disclosed
US-8907103-B2 Glucagon antagonists METABASIS THERAPEUTICS, INC. (US) 2014-12-09 — — US disclosed
EP-2799428-A2 Glucagon antagonists Metabasis Therapeutics, Inc. (US) 2014-11-05 — — EP disclosed
EP-2326618-B1 GLUCAGON ANTAGONISTS METABASIS THERAPEUTICS INC (US) 2014-10-15 — — EP disclosed
US-20130030029-A1 Glucagon Antagonists METABASIS THERAPEUTICS, INC. (US) 2013-01-31 — — US disclosed
CN-102292316-A Glucagon antagonists — 2011-12-21 — — CN disclosed
EP-2326618-A1 GLUCAGON ANTAGONISTS Metabasis Therapeutics, Inc. (US) 2011-06-01 — — EP disclosed
WO-2010019830-A1 GLUCAGON ANTAGONISTS METABASIS THERAPEUTICS, INC. (US) 2010-02-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130030029-A1 Glucagon Antagonists GLP1R, GCG, GCGR KMT2A 3865/4885CTSS 1974/4885CTSK 1915/4885
US-20190330144-A1 GLUCAGON ANTAGONISTS GLP1R, GCG, GCGR KMT2A 3865/4885CTSS 1974/4885CTSK 1915/4885
US-20190099391-A1 Glucagon Antagonists GLP1R, GCG, GCGR KMT2A 3774/4885CTSS 1938/4885CTSK 1910/4885
US-20210121422-A1 GLUCAGON RECEPTOR ANTAGONISTS GLP1R, GCGR, GCG KMT2A 2097/4885CTSS 2229/4885CTSK 2248/4885
US-11352321-B2 Glucagon antagonists GLP1R, GCG, GCGR KMT2A 3865/4885CTSS 1974/4885CTSK 1915/4885
US-20150087680-A1 GLUCAGON ANTAGONISTS GLP1R, GCG, GCGR KMT2A 3865/4885CTSS 1974/4885CTSK 1915/4885
US-12208071-B2 Glucagon receptor antagonists GLP1R, GCGR, GCG KMT2A 2097/4885CTSS 2229/4885CTSK 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.